New book by Larry Connors Click here Improve your trading - See how
MEDIA RELEASE PR35618
SYDNEY, Aug. 6 /PRNewswire-AsiaNet/ --
Growth in innovative targeted therapies set to drive breast cancer therapeutics market in Australia
Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cancer patients in the country was 164,814 in 2008. This figure is estimated to reach 304,511 patients by 2013. Globally, breast cancer is second to lung cancer as the cause of death among women.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117 FSLOGO)
Initiatives such as the BreastScreen Australia program, which provides free mammography services to aid in the early detection of breast cancer, have resulted in oncologists seeing more early stage disease. This, combined with aggressive and targeted therapy has, in turn, resulted in a reduction in the number of locally-advanced and metastatic breast cancer patients in the country.
The use of molecular targeted therapies as effective forms of cancer therapy is becoming more prevalent. These therapies are specifically designed to target cancer cells, while minimizing the adverse effects on normal cells when compared to cytotoxic chemotherapeutic drugs. New offerings must constitute therapies that will improve quality of life and survival rates if they are to thrive in this highly competitive market.
"Biopharmaceutical companies are placing more emphasis on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well," explains Carole Gaffud, Frost & Sullivan Research Analyst. "There are several new targeted therapies and chemotherapy drugs under development, including Epotheliones and Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors."
However, chemotherapy continues to be used widely for now. This may be attributed to the fact that the use of targeted therapy is limited due to access and affordability issues, thereby making those complements rather than substitutes for chemotherapy. "Due to higher cost compared to cytotoxic and hormonal therapies, the use of targeted therapies in Australia is and will continue to be largely dependent on their price and availability on the Pharmaceutical Benefits Scheme (PBS)," says Gaffud.
Currently, only Herceptin (for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer patients) are subsidized through the PBS. Nonetheless, innovative targeted therapies are showing great promise and are being touted as the future of breast cancer treatment. Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies will soon become the standard of oncology care.
Frost & Sullivan's latest research service on The Breast Cancer Therapeutics Market in Australia provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in Australia.
This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team(TM) are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com
Contact:
Jasminder Kaur
Corporate Communications -Healthcare, Asia Pacific
DID: +65 6890 0937
Email: jkaur@frost.com
Emmie Kaur
Corporate Communications -Healthcare, Asia Pacific
DID: +603 6204 5913
Email: emmie.kaur@frost.com
SOURCE: Frost & Sullivan
CONTACT: Jasminder Kaur,
+65 6890 0937,
jkaur@frost.com, or
Emmie Kaur,
+603 6204 5913,
emmie.kaur@frost.com,
both of Corporate Communications-Healthcare,
Asia Pacific of Frost & Sullivan
Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO
bl
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
